Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

janssen-cilag intern. nv.,belgium (0000003234) turnhoutseweg, 30, b-2340 beerse, - ibrutinib - ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ - 140mg/cap - 0936563961 ibrutinib 140.000000 mg - ibrutinib

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

janssen-cilag intern. nv.,belgium (0000003234) turnhoutseweg, 30, b-2340 beerse, - ibrutinib - ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ - 560mg/ΤΑΒ - 0936563961 ibrutinib 140.000000 mg - ibrutinib

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

janssen-cilag intern. nv.,belgium (0000003234) turnhoutseweg, 30, b-2340 beerse, - ibrutinib - ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ - 140mg/ΤaΒ - 0936563961 ibrutinib 140.000000 mg - ibrutinib

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

janssen-cilag intern. nv.,belgium (0000003234) turnhoutseweg, 30, b-2340 beerse, - ibrutinib - ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ - 280mg/ΤΑΒ - 0936563961 ibrutinib 280.000000 mg - ibrutinib